Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

Trial Profile

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 15 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab; Methotrexate; Varicella zoster virus vaccine live
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORAL STRATEGY
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jun 2019 Results analysing Matching-Adjusted Indirect Comparison (Maic) of upadcitinib versus tofacitinib by taking individual patients data from 4 trials (SELECT-MONOTHERAPY, Oral Standard trial, SELECT-COMPARE, ORAL Strategy trial ), are presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 15 Jun 2019 Results of a post-hoc analysis of ORAL Step, ORAL Scan, ORAL Sync, ORAL Standard, ORAL Solo and ORAL Strategy assessing the frequency and duration of the most common tolerability-related non-serious AEs in patients with RA receiving tofacitinib 5 mg BID (n=2657) presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results of a pooled post-hoc analysis of NCT00550446, ORAL Solo and ORAL Strategy assessing the effect of tofacitinib monotherapy (n=676) presented at the 20th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top